Opus Genetics Inc (IRD) Stock AnalysisIRDStock AnalysisOpus Genetics Inc

Opus Genetics, Inc. is a clinical-stage ophthalmic biotechnology company. The Company is engaged in developing gene therapies for the treatment of inherited retinal diseases (IRDs) and other types of therapies for additional ophthalmic disorders. The Company’s pipeline includes adeno-associated virus (AAV)-based investigational gene therapies that address mutations in genes that cause different forms of bestrophinopathy, Leber congenital amaurosis (LCA) and retinitis pigmentosa. Its pipeline also includes OPGx-BEST1 investigational gene therapy, designed to address mutations in the BEST1 gene, which is associated with retinal degeneration. The pipeline also includes Phentolamine Ophthalmic Solution 0.75%, a non-selective alpha-1 and alpha-2 adrenergic antagonist being investigated to reduce pupil size, and APX3330, a novel small-molecule inhibitor of Ref-1 being investigated to slow the progression of non-proliferative diabetic retinopathy. It operates in the Healthcare sector.

Opus Genetics Inc (IRD) is a good buy right now due to its current price of $3.69, which is significantly lower than analyst price targets of $9 and $13, indicating substantial upside potential. The company's recent alignment with the FDA on its Phase 3 trial design for a gene therapy product is a strong positive catalyst, which could lead to increased investor interest. However, the main risk is the negative net income reported at -65,535,000 USD for Q1 2026, which highlights ongoing financial challenges.